Efficacy and Safety of Saccharomyces Boulardii in Treatment of Acute Diarrhea in Children Aged 6 Months to 5 Years Old

Efficacy and Safety of Saccharomyces Boulardii in Treatment of Acute Diarrhea in Children Aged 6 Months to 5 Years Old

This study aimed to evaluate the effectiveness of saccharomyces-based treatment in children with acute diarrhea aged 6 months to 5 years compared to children treated with standard methods.

A total of 206 children diagnosed with acute diarrhea will be evaluated and divided into two groups based on a random distribution list: Group A and Group B.

Group A will be treated with standard methods including fluid replacement and zinc according to the Ministry of Health's protocol.

Group B will be treated similarly to Group A, but with the addition of Saccharomyces boulardii at a dose of 250 to 750 mg per day until discharge.

Both groups of children will receive the same counseling and monitoring, with guidance provided to parents.

Caregivers are advised to record symptoms and stool diaries daily.

Inclusion Criteria:

• Age from 6 months to 5 years old
• Children are diagnosed with acute diarrhea according to WHO criteria.

Exclusion Criteria:

• Bloody, mucous stools.
• Signs of sepsis requiring admission to the Intensive Care Unit.
• Currently suffering from chronic diseases such as cow's milk protein allergy, nephrotic syndrome, immunodeficiency, and systemic diseases.
• Currently using immunosuppressant drugs.